COVID-19 Antibody Therapy: GigaGen Initiates Development of rCIG
by Press Release from Outbreak News Today on (#51FKH)
Biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, GigaGen, announced today it has been developing a recombinant polyclonal antibody therapy for the treatment of COVID-19. The therapy in development, rCIG (recombinant anti-coronavirus 19 hyperimmune gammaglobulin), reproduces whole antibody repertoires of recovered COVID-19 patients, including high concentrations of those antibodies ["]
The post COVID-19 Antibody Therapy: GigaGen Initiates Development of rCIG appeared first on Outbreak News Today.